Why Is PRECIGEN INC (PGEN) Stock Down Today?

Precigen Inc (PGEN) shares fell 18.20% to $4.14 on November 5, 2026. The decline followed the company’s third-quarter earnings report, which showed revenue of $74.1 million and earnings per share of $0.08, both exceeding analyst estimates. Despite the top-line beat, the stock dropped as investors weighed the approval of a rival treatment for the company’s lead product.

What Happened

Precigen reported Q3 2026 results via an 8-K filing on November 5, disclosing revenue of $74.1 million against a consensus estimate of $71.558 million. The company also reported an EPS of $0.08, beating the expected $0.07. While the financials indicated a triple-digit revenue surge and a first profitable stretch, the stock reacted negatively to news that a rival RRP treatment received approval.

Citizens raised its Q4 sales forecast for Papzimeos to $88 million from $65 million and lifted its price target to $12 from $11. The firm maintained a Market Outperform rating, citing strong sales performance. The earnings call transcript, released on November 4, highlighted a bold defense strategy against incoming competition.

What The Data Shows

The stock opened at $4.94, a 2.3% gap down from the prior close of $5.05. It hit a session high of $4.95 at 7:00 AM ET before sliding to a low of $4.10 at 9:40 AM ET. Volume reached 6.4 million shares, which is 1.2 times the three-month daily average.

Fundamentals show a market cap of $1.9 billion with a trailing twelve-month EPS of -$0.98. Revenue growth stands at 1875.0% TTM, though the net margin is -184.0%. The stock printed seven fresh 52-week lows on November 5, 2026. Over the last eight sessions, the stock has moved down 16.2%. Insider activity in the last 90 days includes four sells totaling $2.6 million and one buy for $25,000. Recent sales were filed by Director Jeffrey B Kindler, Chief Commercial Officer Phil Tennant, and COO Rutul R Shah.

What To Watch

Investors will monitor the impact of the newly approved rival RRP treatment on Papzimeos sales. The upcoming earnings date is not specified in the provided data, but coverage breadth remains high with 11 stories from 7 sources in the last 36 hours.